BRICANYL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bricanyl, and when can generic versions of Bricanyl launch?
Bricanyl is a drug marketed by Sanofi Aventis Us and is included in three NDAs.
The generic ingredient in BRICANYL is terbutaline sulfate. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the terbutaline sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bricanyl
A generic version of BRICANYL was approved as terbutaline sulfate by IMPAX LABS on June 26th, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BRICANYL?
- What are the global sales for BRICANYL?
- What is Average Wholesale Price for BRICANYL?
Summary for BRICANYL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 47 |
| Clinical Trials: | 9 |
| Patent Applications: | 3,886 |
| DailyMed Link: | BRICANYL at DailyMed |
Recent Clinical Trials for BRICANYL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Monastir | Phase 1 |
| Yaakov Beilin | Phase 2/Phase 3 |
| University of Monastir | Phase 3 |
US Patents and Regulatory Information for BRICANYL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | BRICANYL | terbutaline sulfate | AEROSOL, METERED;INHALATION | 018000-001 | Mar 19, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | BRICANYL | terbutaline sulfate | TABLET;ORAL | 017618-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | BRICANYL | terbutaline sulfate | INJECTABLE;INJECTION | 017466-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | BRICANYL | terbutaline sulfate | TABLET;ORAL | 017618-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BRICANYL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | BRICANYL | terbutaline sulfate | AEROSOL, METERED;INHALATION | 018000-001 | Mar 19, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | BRICANYL | terbutaline sulfate | INJECTABLE;INJECTION | 017466-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | BRICANYL | terbutaline sulfate | TABLET;ORAL | 017618-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | BRICANYL | terbutaline sulfate | TABLET;ORAL | 017618-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | BRICANYL | terbutaline sulfate | TABLET;ORAL | 017618-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | BRICANYL | terbutaline sulfate | TABLET;ORAL | 017618-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | BRICANYL | terbutaline sulfate | INJECTABLE;INJECTION | 017466-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BRICANYL
See the table below for patents covering BRICANYL around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
